STOCK TITAN
  1. Home
  2. News
  3. ROIV

Roivant Sciences Ltd. Common Shares - ROIV STOCK NEWS

Welcome to our dedicated page for Roivant Sciences Ltd. Common Shares news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences Ltd. Common Shares stock.

Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to revolutionize healthcare by accelerating the development and commercialization of crucial medicines. With a mission to bring innovative treatments to market swiftly, Roivant builds nimble subsidiaries known as 'Vants' to optimize efficiency in pharma R&D and commercialization.

Roivant’s diversified pipeline includes VTAMA®, a novel topical approved for psoriasis and in development for atopic dermatitis, along with other promising drug candidates such as batoclimab, IMVT-1402, and brepocitinib. These candidates are being developed for various autoimmune and inflammatory conditions, including non-infectious uveitis, dermatomyositis, and other IgG-mediated autoimmune indications.

The company’s strategy involves forming strategic partnerships with leading academic institutions and biopharmaceutical companies to enhance its therapeutic portfolio. Notably, collaborations with Takeda, Priovant, and Immunovant have bolstered its drug development capabilities.

Recent advancements include significant progress in clinical trials, such as positive Phase 2 results for brepocitinib in non-infectious uveitis and the successful launch of VTAMA for psoriasis. Additionally, Roivant's acquisition of Telavant and robust financial performance underscore its growth trajectory and commitment to addressing unmet medical needs.

Roivant’s innovative approach also extends to incubating discovery-stage companies and health technology startups, ensuring a continuous pipeline of next-generation therapies. The company’s forward-thinking model focuses on areas with high societal medical needs, aiming to deliver impactful solutions to patients globally.

For more detailed and up-to-date information on Roivant Sciences Ltd., visit their official website.

News

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Rhea-AI Summary
Roivant (Nasdaq: ROIV) completes the acquisition of Telavant by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $7.1 billion, with an upfront payment and a near-term milestone payment. Telavant holds rights to RVT-3101, a therapy for inflammatory bowel disease in the US and Japan. Roivant previously owned 75% of Telavant's shares. Roche aims to continue RVT-3101's development across multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
acquisition
-
News

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Rhea-AI Summary
Immunovant, Inc. (IMVT) announced initial data from the 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402, showing that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, with minimal changes in albumin and LDL-C, confirming the potential of IMVT-1402 as a best-in-class FcRn inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Rhea-AI Summary
Roivant (ROIV) and Priovant announce that the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. However, Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) due to the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study. Priovant also expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU) in the first quarter of calendar year 2024 and topline results from the Phase 3 trial in dermatomyositis (DM) in calendar year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
clinical trial
News

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Rhea-AI Summary
Roivant (ROIV) reported a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M. IMVT-1402 SC doses achieved peak IgG reductions similar to batoclimab. VTAMA® cream generated $18.4M in net product revenue for the quarter. Cash, cash equivalents, and restricted cash were approximately $1.4B at September 30, 2023, expected to reach $7.0B with pending sale proceeds. Mayukh Sukhatme, M.D. appointed to the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
earnings
-
News

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

Rhea-AI Summary
Roivant (Nasdaq: ROIV) appoints Mayukh Sukhatme, M.D., as a new member of its Board of Directors, expanding the board to eight members. Dr. Sukhatme's extensive experience in the pharmaceutical industry and his role in driving positive Phase 3 studies and FDA approvals make him a valuable addition to the board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
management
-
News

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a live conference call and webcast on November 13, 2023, to report its Q2 2023 financial results and provide a business update. The conference call will be accessible via phone registration and the webcast will be available on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences earnings
News

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Rhea-AI Summary
Roche has entered into a definitive agreement with Roivant to acquire Telavant Holdings, gaining the rights to develop and commercialize RVT-3101, a novel TL1A directed antibody for the treatment of inflammatory bowel disease. Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. The agreement also includes an option for a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.02%
Tags
acquisition
-
News

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

Rhea-AI Summary
Lokavant receives $8 million investment from Mitsui & Co. Ltd. to expand its AI-optimized platform in the APAC region. Lokavant to open new APAC headquarters in Tokyo. Mitsui pledges operational support for business development and product localization. Lokavant has raised a total of $29 million in funding. Lokavant's platform provides significant value to pharmaceutical sponsors and CROs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
clinical trial AI
-
News

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Rhea-AI Summary
IMVT-1402 subcutaneous doses showed dose-dependent reductions in IgG with no adverse effects on serum albumin or LDL-C levels. Initial data supports IMVT-1402 as a potential best-in-class FcRn inhibitor. Mean total IgG reduction from baseline in the 300 mg MAD cohort was 63%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.55%
Tags
clinical trial
News

Roivant Announces Completion of Redemption of its Outstanding Warrants

Rhea-AI Summary
Roivant completes redemption of outstanding warrants at $0.10 per warrant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
none

FAQ

What is the current stock price of Roivant Sciences Ltd. Common Shares (ROIV)?

The current stock price of Roivant Sciences Ltd. Common Shares (ROIV) is $11.57 as of December 20, 2024.

What is the market cap of Roivant Sciences Ltd. Common Shares (ROIV)?

The market cap of Roivant Sciences Ltd. Common Shares (ROIV) is approximately 8.3B.

What is Roivant Sciences Ltd. known for?

Roivant Sciences Ltd. is known for its innovative approach to rapidly developing and commercializing new medicines, primarily through its nimble subsidiaries called 'Vants'.

What are the key products in Roivant's pipeline?

Key products include VTAMA® for psoriasis, batoclimab and IMVT-1402 for autoimmune conditions, and brepocitinib for dermatomyositis and non-infectious uveitis.

What is the goal of Roivant’s business model?

The goal of Roivant’s business model is to accelerate the development and commercialization of important medicines, ensuring they rapidly reach patients with serious diseases.

Who are some of Roivant’s strategic partners?

Roivant has partnered with leading academic institutions and biopharmaceutical companies, including Takeda, Priovant, and Immunovant.

What recent achievements has Roivant made?

Recent achievements include positive Phase 2 trial results for brepocitinib in non-infectious uveitis and the commercial launch of VTAMA for psoriasis.

How does Roivant's 'Vant' model work?

Roivant’s 'Vant' model involves creating nimble, entrepreneurial biotech companies that specialize in developing and commercializing specific medicines and technologies efficiently.

What is VTAMA® used for?

VTAMA® is a novel topical treatment approved for psoriasis and is also being developed for atopic dermatitis.

How does Roivant contribute to innovation in drug development?

Roivant accelerates innovation by reducing the time and cost of drug development, leveraging technology, and forming strategic collaborations to drive efficiency in R&D.

Why is Roivant’s approach significant?

Roivant’s approach is significant because it addresses areas with high unmet medical needs, ensuring that vital medications reach patients faster and more cost-effectively.

Where can I find more information about Roivant?

More information about Roivant Sciences Ltd. can be found on their official website at www.roivant.com.

Stock ROIV logo
Roivant Sciences Ltd. Common Shares

Nasdaq:ROIV

ROIV Rankings

#952 Ranked by Market Cap
N/A Ranked by Dividends

ROIV Stock Data

8.32B
506.93M
29.42%
79.49%
5.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAMILTON HM11